Literature DB >> 18640236

Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment.

Lauren M Aleksunes1, Lisa M Augustine, George L Scheffer, Nathan J Cherrington, José E Manautou.   

Abstract

The goal of this study was to identify alterations in mRNA and protein expression of various xenobiotic transport proteins in mouse kidney during cisplatin-induced acute renal failure. For this purpose, male C57BL/6J mice received a single dose of cisplatin (18 mg/kg, i.p.) or vehicle. Four days later, tissues were collected for assessment of plasma BUN, histopathological analysis of renal lesions, and mRNA and Western blot analysis of renal transporters including organic anion and cation transporters (Oat, Oct), organic anion transporting polypeptides (Oatp), multidrug resistance-associated proteins (Mrp), multidrug resistance proteins (Mdr), breast cancer resistance protein (Bcrp) and multidrug and toxin extrusion proteins (Mate). Cisplatin treatment caused necrosis of renal proximal tubules along with elevated plasma BUN and renal kidney injury molecule-1 mRNA expression. Cisplatin-induced renal injury increased mRNA and protein levels of the efflux transporters Mrp2, Mrp4, Mrp5, Mdr1a and Mdr1b. Uptake transporters Oatp2a1 and Oatp2b1 mRNA were also up-regulated following cisplatin. By contrast, expression of Oat1, Oat2, Oct2 and Oatp1a1 mRNA was reduced in cisplatin-treated mice. Expression of several uptake and efflux transporters was unchanged in cisplatin-treated mice. Apical staining of Mrp2 and Mrp4 proteins was enhanced in proximal tubules from cisplatin-treated mice. Collectively, these expression patterns suggest coordinated regulation of uptake and efflux pathways during cisplatin-induced renal injury. Reduced expression of basolateral and apical uptake transporters along with enhanced transcription of export transporters likely represents an adaptation to lower intracellular accumulation of chemicals, prevent their reabsorption and enhance urinary clearance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640236      PMCID: PMC2570650          DOI: 10.1016/j.tox.2008.06.009

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  33 in total

1.  Tissue distribution and ontogeny of organic cation transporters in mice.

Authors:  Yazen Alnouti; Jay S Petrick; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2005-12-28       Impact factor: 3.922

2.  RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.

Authors:  Verena Materna; Alexandra Stege; Pawel Surowiak; Axel Priebsch; Hermann Lage
Journal:  Biochem Biophys Res Commun       Date:  2006-07-14       Impact factor: 3.575

3.  Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).

Authors:  Atsushi Yonezawa; Satohiro Masuda; Sachiko Yokoo; Toshiya Katsura; Ken-Ichi Inui
Journal:  J Pharmacol Exp Ther       Date:  2006-08-16       Impact factor: 4.030

4.  Short-term exposure of renal proximal tubules to gentamicin increases long-term multidrug resistance protein 2 (Abcc2) transport function and reduces nephrotoxicant sensitivity.

Authors:  Sylvia Notenboom; David S Miller; Leon H Kuik; Paul Smits; Frans G M Russel; Rosalinde Masereeuw
Journal:  J Pharmacol Exp Ther       Date:  2005-08-05       Impact factor: 4.030

5.  Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.

Authors:  Maria Rius; Johanna Hummel-Eisenbeiss; Alan F Hofmann; Dietrich Keppler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-11-10       Impact factor: 4.052

6.  Prostanoid transport by multidrug resistance protein 4 (MRP4/ABCC4) localized in tissues of the human urogenital tract.

Authors:  Maria Rius; Walter F Thon; Dietrich Keppler; Anne T Nies
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

7.  Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.

Authors:  Stacy S Shord; David M Thompson; Greg A Krempl; Marie H Hanigan
Journal:  Anticancer Drugs       Date:  2006-02       Impact factor: 2.248

8.  MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus).

Authors:  David S Miller; Joseph R Shaw; Caitlin R Stanton; Roxanna Barnaby; Katherine H Karlson; Joshua W Hamilton; Bruce A Stanton
Journal:  Toxicol Sci       Date:  2007-02-25       Impact factor: 4.849

9.  Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2.

Authors:  Giuliano Ciarimboli; Thomas Ludwig; Detlef Lang; Hermann Pavenstädt; Hermann Koepsell; Hans-Jürgen Piechota; Jörg Haier; Ulrich Jaehde; Jochen Zisowsky; Eberhard Schlatter
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

10.  Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.

Authors:  Sachiko Yokoo; Atsushi Yonezawa; Satohiro Masuda; Atsushi Fukatsu; Toshiya Katsura; Ken-Ichi Inui
Journal:  Biochem Pharmacol       Date:  2007-03-12       Impact factor: 5.858

View more
  22 in total

1.  Renal efflux transporter expression in pregnant mice with Type I diabetes.

Authors:  Lindsay L Yacovino; Lauren M Aleksunes
Journal:  Toxicol Lett       Date:  2012-04-17       Impact factor: 4.372

Review 2.  Regulatory pathways for ATP-binding cassette transport proteins in kidney proximal tubules.

Authors:  Rosalinde Masereeuw; Frans G M Russel
Journal:  AAPS J       Date:  2012-09-08       Impact factor: 4.009

3.  Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.

Authors:  Lauren M Aleksunes; Michael J Goedken; Cheryl E Rockwell; Juergen Thomale; Jose E Manautou; Curtis D Klaassen
Journal:  J Pharmacol Exp Ther       Date:  2010-07-06       Impact factor: 4.030

4.  Mechanism of kidney injury caused by bevacizumab in rats.

Authors:  Ning Zhao; Qunhong Xu; Ming Wang; Xiao Fei; Yuelong Pan; Xueqing Chen; Shenglin Ma
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

5.  Altered arsenic disposition in experimental nonalcoholic fatty liver disease.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Michael J Kopplin; George L Scheffer; Walter T Klimecki; A Jay Gandolfi; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2012-06-14       Impact factor: 3.922

6.  Vitamin C Deficiency Causes Cell Type-Specific Epigenetic Reprogramming and Acute Tubular Necrosis in a Mouse Model.

Authors:  Zihui Yu; Ziying Xu; Yuan Liang; Pengbin Yin; Yue Shi; Jiayi Yu; Junfeng Hao; Ting Wang; Weimin Ci
Journal:  J Am Soc Nephrol       Date:  2022-01-04       Impact factor: 10.121

Review 7.  Polymorphic transporters and platinum pharmacodynamics.

Authors:  Jason A Sprowl; Rachel A Ness; Alex Sparreboom
Journal:  Drug Metab Pharmacokinet       Date:  2012-09-18       Impact factor: 3.614

8.  Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation.

Authors:  Malvika H Solanki; Prodyot K Chatterjee; Madhu Gupta; Xiangying Xue; Andrei Plagov; Margot H Metz; Rachel Mintz; Pravin C Singhal; Christine N Metz
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-18

Review 9.  Environmental pollution and kidney diseases.

Authors:  Xin Xu; Sheng Nie; Hanying Ding; Fan Fan Hou
Journal:  Nat Rev Nephrol       Date:  2018-02-26       Impact factor: 28.314

10.  ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma.

Authors:  Tony Huynh; Murray D Norris; Michelle Haber; Michelle J Henderson
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.